Literature DB >> 16270035

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.

A Tchirkov, J-L Couderc, B Périssel, C Goumy, A Regnier, N Uhrhammer, P Verrelle, M Berger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16270035      PMCID： PMC1931492          DOI： 10.1038/sj.leu.2404012

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma.

Authors:  P Martiat; C Mecucci; Y Nizet; M Stul; M Philippe; J J Cassiman; J L Michaux; H Van den Berghe; G Sokal
Journal:  Leukemia       Date:  1990-11       Impact factor: 11.528

Review 2.  e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?

Authors:  S Demehri; P Paschka; B Schultheis; T Lange; T Koizumi; T Sugimoto; S Branford; L C Lim; T Kegel; G Martinelli; A Hochhaus; B J Druker; M W N Deininger
Journal:  Leukemia       Date:  2005-04       Impact factor: 11.528

3.  Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Authors:  Jorge Cortes; Moshe Talpaz; Susan O'Brien; Dan Jones; Rajyalakshmi Luthra; Jenny Shan; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Mary B Rios; Hagop Kantarjian
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

Review 4.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

5.  MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures.

Authors:  J D Cashman; C J Eaves; A H Sarris; A C Eaves
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113
  5 in total
  5 in total

1.  Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.

Authors:  Nathalie Sorel; Caroline Mayeur-Rousse; Séverine Deverrière; Lydia Roy; Elisabeth Brottier-Mancini; François Guilhot; Ali G Turhan; Jean Claude Chomel
Journal:  J Mol Diagn       Date:  2010-05-27       Impact factor: 5.568

2.  A Novel e8a2BCR-ABL1 Fusion Transcript without Insertion Sequence in a Patient with Chronic Myeloid Leukemia.

Authors:  Caibao Jin; Xiaojian Zhu; Min Xiao; Songya Liu; Xian Liu; Jingjing Liu; Xiuwen Xu; Shujuan Yi; Li Meng
Journal:  Ann Lab Med       Date:  2018-03       Impact factor: 3.464

3.  Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.

Authors:  Shuang Fu; Yanping Hu; Yu Fu; Fang Chen; Xuan Liu; Minyu Zhang; Xiaohui Wang; Shichun Tu; Jihong Zhang
Journal:  Cancer Biol Ther       Date:  2016-09-10       Impact factor: 4.742

4.  A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia.

Authors:  Xiaodong Lyu; Jingke Yang; Xianwei Wang; Jieying Hu; Bing Liu; Yu Zhao; Zhen Guo; Bingshan Liu; Ruihua Fan; Yongping Song
Journal:  Mol Cytogenet       Date:  2016-06-27       Impact factor: 2.009

5.  A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript.

Authors:  Aleksandra Mroczkowska; Bożena Jaźwiec; Justyna Urbańska-Rakus; Sylwia Szymanowska; Anna Tessmann; Sonia Pająk; Katarzyna Machnik; Olga Haus; Tomasz Wróbel
Journal:  BMC Med Genomics       Date:  2022-02-05       Impact factor: 3.063
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.